ProShare Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA

ProShare Advisors LLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 9,189 shares of the company’s stock, valued at approximately $279,000.

Several other hedge funds have also recently added to or reduced their stakes in ORKA. Fairmount Funds Management LLC grew its position in Oruka Therapeutics by 9.9% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after purchasing an additional 333,340 shares in the last quarter. Secure Asset Management LLC purchased a new position in Oruka Therapeutics during the 4th quarter worth approximately $2,475,000. Avoro Capital Advisors LLC purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $296,000. Finally, Commodore Capital LP grew its position in Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after purchasing an additional 333,340 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on ORKA. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday, April 27th. BTIG Research reissued a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Barclays lifted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

Insider Buying and Selling at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the sale, the senior vice president owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. The trade was a 38.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. The trade was a 58.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,055 shares of company stock worth $8,095,785 in the last 90 days. 23.49% of the stock is currently owned by company insiders.

Oruka Therapeutics Stock Performance

ORKA stock opened at $58.53 on Monday. Oruka Therapeutics, Inc. has a 1 year low of $10.64 and a 1 year high of $91.00. The company has a fifty day simple moving average of $59.69 and a 200 day simple moving average of $41.63. The firm has a market cap of $3.53 billion, a PE ratio of -30.17 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.